In support of the concept that VEGF is a critical angiogenic regulator, G6-31 treatment also led to prevention and reversal of mucocutaneous AVMs in Alk1-iKOe mouse model of HHT (Han et al., 2014), indicating that a reduction in VEGF levels is able to inhibit the growth of AVMs. The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.